Only 8 Weeks away9 Mar 2023 20:37
William W. Bachovchin reviewing how well AVA6000 is working in May.
“We have designed, characterized and optimized a number of prodrugs activated by FAP and will review how well these are working and how they might be improved still further.”
William W. Bachovchin, Ph.D., is a Professor in the Department of Developmental, Molecular and Chemical Biology at Tufts University School of Medicine. His research has focused on the mechanisms and biological functions of serine proteases including drug design and development targeting these enzymes. He has invented a range of drugs that have progressed into human clinical trials. These include the small molecule IO agent Talabostat and more recently the precision radiopharmaceutical and chemotherapeutic drugs PNT6555 and AVA6000 respectively. His research also includes the discovery of the role of DPP4 in diabetes which led to a patent that has been licensed to Merck and other Pharma companies for their gliptin drugs
https://informaconnect.com/tides/speakers/william-bachovchin-phd/
May 7-10, 2023 | In-Person + Digital?San Diego, CA, USA,?Manchester Grand Hyatt San Diego
Presentation
Tumor Activated Prodrugs Utilizing Fibroblast Activation Protein (FAP)
FAP is a serine protease with an unusual specificity, in that it cleaves after proline, and an unusual expression profile, in that it is selectively and highly overexpressed in most human tumor tissues. These two factors combine to make it a reasonable choice to target in designing tumor activated prodrugs. We have designed, characterized and optimized a number of prodrugs activated by FAP and will review how well these are working and how they might be improved still further.
Sign In
Follow the stocks
